AvaMed hopes to secure enough Congressional support to repeal the 2.3% medical excise tax before implementation on January 1. AvaMed plans to reiterate the negative effects of the policy to the industry and capitalize on any opportunities to challenge the tax. In a recent article by Fierce Medical Devices, the device tax has become increasingly complicated as “companies including Welch Allyn have already slashed jobs or retrenched from expansion plans” stating the tax was to blame.

To read the full article regarding the device tax issue, click here.